Home › Onglyza (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating ...
 

Keywords :   


Onglyza (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating ...

2013-09-02 10:10:35| Biotech - Topix.net

Onglyza Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial AstraZeneca and Bristol-Myers Squibb Company today announced the full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular ... (more)

Tags: primary safety demonstrating achieves

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
01.11Tropical Depression Thirteen-E Forecast Discussion Number 1
01.11Tropical Depression Thirteen-E Graphics
01.11Tropical Depression Thirteen-E Wind Speed Probabilities Number 1
01.11Summary for Tropical Depression Thirteen-E (EP3/EP132024)
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
01.11CERM launches new MIS products, Mark Andy innovates and more
01.11Removing a major trade barrier: Full access to Colombia restored for U.S. beef
More »